Dapagliflozin treatment is associated with a reduction of epicardial adipose tissue thickness and epicardial glucose uptake in human type 2 diabetes

Dapagliflozin treatment is associated with a reduction of epicardial adipose tissue thickness and epicardial glucose uptake in human type 2 diabetes

Abstract Objective We recently demonstrated that treatment with sodium-glucose cotransporter-2 inhibitors (SGLT-2i) leads to an increase in myocardial flow reserve in patients with type 2 diabetes (T2D) with stable coronary artery disease (CAD). The mechanism by which this occurs is, however, unclea...

Full description

Bibliographic Details
Main Authors: Francesca Cinti, Lucia Leccisotti, Gian Pio Sorice, Umberto Capece, Domenico D’Amario, Margherita Lorusso, Shawn Gugliandolo, Cassandra Morciano, Andrea Guarneri, Maria Angela Guzzardi, Teresa Mezza, Amedeo Capotosti, Luca Indovina, Pietro Manuel Ferraro, Patricia Iozzo, Filippo Crea, Alessandro Giordano, Andrea Giaccari
Format: Article
Language:English
Published: BMC 2023-12-01
Series:Cardiovascular Diabetology
Subjects:
Diabetes
Metabolism
Epicardial adipose tissue
PET
SGLT-2i
Microvascular dysfunction
Online Access:https://doi.org/10.1186/s12933-023-02091-0

Similar Items

Similar Items